Histopathological Grade Versus Hormone Receptor Status In Breast Carcinoma- Treasure The Past
Introduction: Breast carcinoma is the most common cancer among women. Prognosis and management of breast cancer are influenced by classic variables such as grade, stage, hormone receptor status of estrogen (ER), progesterone (PR) & Her2/neu over expression. Though hormone receptor analysis is a prerequisite in this era, for management and prognosis, still histopathological grading can be taken up as an important variable for predicting prognosis.An attempt has been made in this study to correlate histopathological grade with hormone receptor status in breast carcinomas in our institution.
Objectives: To correlate the Histopathological grade with ER, PR and Her2/neu receptor status of breast carcinoma
Materials & Methods: A prospective study conducted from June 2011 to June 2014 in the department of Pathology, ESIC Medical College & PGIMSR, ESIC Model Hospital, Rajajinagar, Bangalore. Hundred Modified radical mastectomy specimens were subjected for routine histological examination and Immunohistochemical analysis. Clinical details were archived from the files. Statistical analysis was done and p value of <0.05 were taken as significant using chi-square test.
Results: The age of the patients ranged from 24 to 75 years. Majority of tumours were predominantly of histopathological grade two. By Immunohistochemistry 52% were ER+/PR+, 25% were Her2/neu positive and 20% of triple negatives. A significant association was seen between histologic grade and hormone receptor status.
Conclusion: Histologic gradingtogether with receptor status offers an excellent method of correlation of survival rate and response to hormonal therapy which lightens up a prospect of various treatment modalities.
National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In, Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR). 2006; 8-30.
Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer breast in India: a summary. Indian J Surg Oncol. 2010; 1:8-9.
Murthy N S, Chaudhry K, Nadayil D, Agarwal U K, Saxena S. Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer 2009; 46:73.
Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral centre in India: What was and what is. Indian J Pathol Microbiol 2009; 50:284-90.
Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011;48:391-6
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. Asian Pacific J Cancer Prev 2011; 12:625-629
Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008; 9:553-6.
SuvarchalaSB,NageshwararaoR.Carcinoma Breast-Histopathological and hormone receptors correlation. J Biosci Tech 2011:2; 340-48.
Pakseresht S, Ingle G K, Bahadur A K, Ramteke V K, Singh M M, Garg S, Agarwal P N. Risk factors with breast cancer among women in Delhi. Indian J Cancer 2009; 46:132-8.
Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000; 53: 688-96.
Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer 2010; 47:16-22.
Adedayo AO, Engel JM, Greenlee RT, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res. 2009; 7: 413.
Aryandono T, Harijadi, Soeripto. Hormone receptor status of operable breast cancers in Indonesia: correlation with other prognostic factors and survival. Asian Pac J Cancer Prev 2006; 7: 321-4
Sharif MA, Mamoon N, Mushtaq S, Khadim MT, Jamal S. Steroid Hormone Receptor Association with Prognostic Markers in Breast Carcinoma in Northern Pakistan. J Coll Physicians Surg Pak. 2010; 20: 181-85.
Chopra R. The Indian Scene. J Clin Oncol. 2001; 19:106-111.
Kuraparthy S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Reddy RPV. Epidemiology and patterns of care for invasive breast carcinoma ata community hospital in Southern India. World J Surg Oncol. 2007; 5:56
Goyanes RIA, Perez XE,Rodriguez RC, Lopez MO, Odio SF, Fernandez LL, Yi MG, Padilla CR. Hormone Receptors and Other Prognostic Factors in Breast Cancer in Cuba. MEDICC Review, 2010; 12: 36-40.
Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast CancTarg Ther. 2011; 3: 919.
Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB- 2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer. 2010; 47: 8-15.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano .Descriptive analysis of Estrogen Receptor(ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the so-called Triple-Negative Phenotype. Cancer 2007;109:1721-8.
Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K . Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in Infiltrative Breast Carcinomas in Indian Patients. Asian Pac J Cancer Prev 2009; 10: 773-78.
Maynard PV, Davies CJ, Blamey RW. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer.1978; 38: 745-8.
Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US- a SEER analysis. BMC cancer. 2010; 10:191.
Rakha EA, El-Sayed ME, Green AR. Prognostic markers in triple negative breast cancer. Cancer 2007; 109:2532.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403410.
Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of Her-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad 2008; 20(3):23-26.
Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008; 113: 608-15.
Copyright (c) 2015 International Journal of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.